Exelixis
EXEL
#1695
Rank
A$15.22 B
Marketcap
$53.32
Share price
0.23%
Change (1 day)
67.21%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): A$0.88 Billion

According to Exelixis's latest financial reports the company's current earnings are A$2.08 Billion. In 2023 the company made an earning of A$0.39 Billion, an increase over its 2022 earnings that were of A$0.35 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) A$0.88 B124.63%
2023 A$0.39 B9.89%
2022 A$0.35 B-20.33%
2021 A$0.45 B124.82%
2020 A$0.20 B-67.14%
2019 A$0.61 B-11.94%
2018 A$0.69 B185.09%
2017 A$0.24 B-325.82%
2016 -A$0.11 Billion-58.12%
2015 -A$0.26 Billion-37.61%
2014 -A$0.42 Billion9.75%
2013 -A$0.38 Billion65.96%
2012 -A$0.23 Billion-291.63%
2011 A$0.11 B-195.59%
2010 -A$0.13 Billion-42.17%
2009 -A$0.22 Billion-18.98%
2008 -A$0.27 Billion-6.99%
2007 -A$0.29 Billion46.3%
2006 -A$0.2 Billion33.25%
2005 -A$0.15 Billion-30.92%
2004 -A$0.22 Billion44.29%
2003 -A$0.15 Billion12.86%
2002 -A$0.13 Billion22.79%
2001 -A$0.11 Billion60.14%
2000 -A$65.81 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
A$6.40 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$11.37 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
A$25.31 B 2,648.76%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$10.57 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
A$7.18 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
A$28.24 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$1.87 Billion-302.03%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$71.56 Million-107.77%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$44.59 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA